Objectives: To assess differences in reperfusion treatment and outcomes between secondary and tertiary hospitals in predominantly rural central China.
Design: Multicentre, prospective and observational study.
Setting: Sixty-six (50 secondary and 16 tertiary) hospitals in Henan province, central China.
Participants: Patients with ST elevation myocardial infarction (STEMI) within 30 days of symptom onset during 2016-2018.
Primary outcome measures: In-hospital mortality, and in-hospital death or treatment withdrawal.
Results: Among 5063 patients of STEMI, 2553 were treated at secondary hospitals. Reperfusion (82.0% vs 73.0%, p<0.001) including fibrinolytic therapy (70.3% vs 4.4%, p<0.001) were more preformed, whereas primary percutaneous coronary intervention (11.7% vs 68.6%, p<0.001) were less frequent at secondary hospitals. In secondary hospitals, 53% received fibrinolytic therapy 3 hours after onset, and 5.8% underwent coronary angiography 2-24 hours after fibrinolysis. Secondary hospitals had a shorter onset-to-first-medical-contact time (176 min vs 270 min, p<0.001). Adjusted in-hospital mortality (adjusted OR 1.23, 95% CI 0.89 to 1.70, p=0.210) and in-hospital death or treatment withdrawal (adjusted OR 1.18, 95% CI 0.82 to 1.70, p=0.361) were similar between secondary and tertiary hospitals.
Conclusions: With fibrinolytic therapy as the main reperfusion strategy, the reperfusion rate was higher in secondary hospitals, whereas in-hospital outcomes were similar compared with tertiary hospitals. Public awareness, capacity of primary and secondary care institutes to treat STEMI, and establishment of deeper cooperation among different-level healthcare institutes need to further improve.
Trial registration number: NCT02641262.
Keywords: adult intensive & critical care; coronary heart disease; coronary intervention; myocardial infarction; quality in health care.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.